{"id":"dose-dense-ac-followed-by-t-trastuzumab","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Cardiotoxicity/congestive heart failure"},{"rate":"50-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"40-60","effect":"Nausea/vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"20-40","effect":"Peripheral neuropathy"},{"rate":"50-70","effect":"Fatigue"},{"rate":"5-10","effect":"Infusion reactions"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:20:46.151240","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dose-dense AC (doxorubicin/cyclophosphamide) delivers chemotherapy at higher doses over shorter intervals to maximize cancer cell kill. Paclitaxel (T) is a taxane that stabilizes microtubules and prevents cell division. Trastuzumab is a monoclonal antibody targeting HER2 receptor on cancer cells, blocking growth signaling and recruiting immune-mediated cell death. This combination is used as adjuvant or neoadjuvant therapy in HER2-positive breast cancer.","oneSentence":"This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:37:14.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT02379585","phase":"PHASE1, PHASE2","title":"Fasting on Newly Diagnosed Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-01","conditions":"HER2-positive Breast Cancer","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dose dense AC followed by T + trastuzumab","genericName":"Dose dense AC followed by T + trastuzumab","companyName":"Agendia","companyId":"agendia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a chemotherapy regimen combining dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (Herceptin) to treat HER2-positive breast cancer by killing cancer cells and blocking HER2 signaling. Used for HER2-positive early-stage breast cancer (adjuvant or neoadjuvant therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}